Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093285
Filing Date
2024-08-08
Accepted
2024-08-08 06:46:28
Documents
52
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nuvl-20240630.htm   iXBRL 10-Q 2037236
2 EX-31.1 nuvl-ex31_1.htm EX-31.1 16231
3 EX-31.2 nuvl-ex31_2.htm EX-31.2 16240
4 EX-32.1 nuvl-ex32_1.htm EX-32.1 9486
5 EX-32.2 nuvl-ex32_2.htm EX-32.2 8256
6 GRAPHIC img240556275_0.jpg GRAPHIC 173738
  Complete submission text file 0000950170-24-093285.txt   6424608

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nuvl-20240630.xsd EX-101.SCH 745836
55 EXTRACTED XBRL INSTANCE DOCUMENT nuvl-20240630_htm.xml XML 820779
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40671 | Film No.: 241185912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)